Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation
Company Logo

Destroying Cancer at the Speed of Light®

Clinical Study Underway (75 of 100 Patients Treated)
Expected to complete enrollment in 2025
Expected to complete study at the end of 2026


Bullboard - Investor Discussion Forum Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called... see more

TSXV:TLT - Post Discussion

Theralase Technologies Inc. > Enhancing cancer immunotherapy with photodynamic therapy
View:
Comment by Dumbeldorfwhite on Apr 22, 2024 6:17am
Not relevant to this board
Comment by wildbird1 on Apr 22, 2024 8:03am
Thank's Oden6570 very good link... As we speak for safety purpose the FDA doesn't allow immunotherapy drugs to treat immunodeficients patients. Combining Immunotherapy drugs with PDT could help resolve that situation. But that is a long way to go,for now TLT must concentrate all it's efforts on getting NMIBC BTD approval. Note; The above combination(immunotherapy + PDT) could be very ...more  
Comment by wildbird1 on Apr 22, 2024 11:01am
Silly me,I forgot to include the link to prove my point. In this link.... paragraph no 3... https://cancer.gov/news-events/cancer-currents-blog/2019/immunotherapy-cancer-autoimmune-diseases-clinical-trial It said... '' Doctors have not know whether immunotherapy is safe and effective for people who have both cancer and autoimmune disease,because such patients heve been excluded from ...more  
Comment by Eoganacht on Apr 22, 2024 12:28pm
This article would be much improved if only the authors were familiar with Dr. McFarland's work. Dr. McFarland has done a lot to overcome the challenges to effective PDT noted by the authors.  2.3.4 Challenges in translating PDT into clinical practice The advancement of PDT into clinical application will confront several challenges that necessitate further development and ...more  
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.


Connect with V.TLT



Investor Presentation

View the Presentation

FACT SHEET

View the Presentation

The Watchlist

The Watchlist
{{currentVideo.videoCaption}}
< Previous Video {{moreVideoText}} Next Video >

Investment Opportunity

The Road to Saving Lives: Clinical Study Underway

  • Clinical Study with 75 of 100 Patients Treated (Enrollment to be completed in 2025, with study completed by end of 2026)
     
  • Ground Floor Investment Opportunity in Multi-Billion Dollar Industry
     
  • Best-in-class treatment for NMIBC (according to interim clinical data)
     
  • NMIBC (Non-Muscle-Invasive Bladder Cancer)
     

Facebook

Contact Us

Address:
41 Hollinger Road
Toronto, ON M4B 3G4
Canada

Toll Free:
1-866-THE-LASE (843-5273)
Local Phone:
416-699-LASE (5273)

Email:
info@theralase.com

Fax:
416-699-5250